Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stimufend vs Neulasta Immunogenicity Study
NCT03251339Phase 1Completed
- Sponsor
- Fresenius Kabi
- Start
- Aug 2017
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Stimufend OBI in neutropenia, sponsored by Fresenius Kabi. Primary endpoint: Immunogenicity of MSB11455 Compared to Neulasta at 3 months. Started Aug 2017; status: completed.
02
Drugs
Stimufend OBI
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03251339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251339.